If you invested $25,000 in AbbVie in 2020, that's what you'd have these days
AbbVie (ABBV 0.Thirteen%) is a blue-
chip healthcare employer that is actually worth nearly $290 billion.
It has a diverse business enterprise
that generates sales from many distinctive areas of healing.
Its bread and butter is the immune drug
Humira, which has already posted a whopping $15.7 billion
But Humira has been both its best product and the trading company's biggest
fear offering, as buyers have been dragged into its patent hold and loss of exclusivity
AbbVie bought Botox maker Allergan in 2020 for a whopping $
63 billion. This is how you would have done it if you had sold the shares after closing the deal.
It's been more than years since AbbVie
completed what's known as a "transformational acquisition" of the Botox maker in 2020.
The deal changed AbbVie, giving it a new cosmetic phase that c
an help add substantial growth opportunities. At the time the deal closed, AbbVie
shares closed at $83,996. In that role, making a $25,000
investment in the health care company would have allowed him to buy about 298 shares.
Need More Stories